High-dose chemotherapy with autologous stem cell support in patients with responding stage IV breast cancer
Per Ljungman(Karolinska University Hospital), Jonas Bergh(Karolinska Institutet), Nils Wilking(Sophiahemmet Hospital), Gunnar Juliusson(Lund University), Annika Malmström(Lund University), Henrik Lindman(Uppsala University), Tommy� Fornander(Karolinska University Hospital), S Rotstein(Danderyds sjukhus), Kenneth Villman(Örebro University Hospital), Martin Höglund(Uppsala University), Martin Söderberg(Uppsala University Hospital), Bo Björkstrand(Karolinska University Hospital)
Cited by 10
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
Clonal Hematopoiesis and Blood-Cancer Risk Inferred from Blood DNA Sequence
|New England Journal of Medicine|2014|3.5k
Pembrolizumab for Early Triple-Negative Breast Cancer
|New England Journal of Medicine|2020|3.1k
3rd ESO–ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 3)
|Annals of Oncology|2016|2.1k